Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | HCK | P08631 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516787 | 0.78 | CHEK1 (0.45) | EGLN2CHEK1PDE10AKDM5BVHL | |
| SCHEMBL1416453 | 0.77 | KDM1A (0.43) | CYP11B2 | |
| SCHEMBL194157 | 0.75 | PIK3CD (0.44) | PIK3CD | |
| SCHEMBL129622 | 0.75 | — | — | |
| SCHEMBL12630708 | 0.75 | CHEK1 (0.51) | EGLN2CHEK1PDE10AKDM5BVHL | |
| SCHEMBL18422759 | 0.75 | MYC (0.44) | MTOR | |
| SCHEMBL14153223 | 0.74 | CHEK1 (0.55) | EGLN2CHEK1 | |
| SCHEMBL18422298 | 0.73 | EGLN2 (0.40) | EGLN2CHEK1SYKPDE10AKDM5B | |
| SCHEMBL18423224 | 0.73 | EGLN2 (0.38) | EGLN2CHEK1SYKPDE10AKDM5B | |
| SCHEMBL2751776 | 0.72 | ALDH1A1 (0.41) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170033293-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | JNC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| CN-101754968-A | Substituted imidazopyridazines as PI3K lipid kinase inhibitors | NOVARTIS AG | 2010-06-23 | — | — | CN | disclosed |
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | EGLN2 2126/4885CHEK1 325/4885SYK 510/4885 |
| US-20170033293-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SLC26A3, SLC9A1, HVCN1 | EGLN2 1111/4885CHEK1 4506/4885SYK 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.